Method of summation-integral equations for solving the mixed problem of nonstationary heat conduction

The solution of a mixed axisymmetric nonstationary problem of heat conduction is obtained in the region of Laplace transforms. In solution of this problem, there occur summation−integral equations with the parameter of the integral Laplace transform (L-parameter) and the additional parameter of the finite integral Hankel transform (H-parameter). The laws governing the development of spatial nonstationary temperature fields in a bounded cylinder and a half-space when one end surface of the cylinder is in contact with the surface of the half-space in a circular region are determined

Solution of mixed contact problems in the theory nonstationary heat conduction by the metod of summation-integral equations

The laws governing the development of spatial nonstationary temperature fields in a bounded cylinder and a half-space where one of the end surfaces of the cylinder touches the surface of the half-space in a circular region are determined. A solution of a mixed axisymmetric nonstationary problem of heat conduction is obtained in the region of Laplace transforms. In solution of this problem, there appear summation-integral equations with the parameter of the integral Laplace transform (L-parameter) and the parameter of the finite integral Hankel transform (H-parameter)

One approach to the analytical solution of a two-dimensional nonstationary problem of heat conduction in regions with moving boundaries on the model of a half-space

With the use of the solution of the Dirichlet nonstationary problem with discontinuous unmixed boundary conditions on the surface of an isotropic half-space a two-dimensional model of the problem with a moving phase boundary is considered. The problem models, for example, the processes of freezing of moist ground or the processes of formation of ice in stagnant water if a temperature lower than the freezing temperature is prescribed on the boundary surface in a circular region of finite radius. The classical one-dimensional result follows as a particular case from solution of this problem for an infinite radius of the circle

The mathematical description of the thermal combined laser and plasma impact on a material

© 2014 Irek Husnemardanovich Israphilov. The mathematical description of process of the thermal combined laser and plasma impact on a material taking into account ring influence of plasma is developed. Results of modeling of process of heating of Steel 45 by laser, ring plasma and combined laser and plasma energy streams

МЕТОД ПОЛУЧЕНИЯ ГРАНИЦ ОБЛАСТЕЙ ОПРЕДЕЛЕНИЯ ФУНКЦИЙ ГЛОБАЛЬНЫХ ЗАВИСИМОСТЕЙ В ЗАДАЧАХ РАСПАРАЛЛЕЛИВАНИЯ ВЫЧИСЛЕНИЙ

A method to obtain the domains of the functions of global dependences based on the refined approximations of the set of tiles is developed. The exact presentation of the boundaries of the domains of the functions of global dependences avoids redundant computations in the performance of communication operations and provides more opportunities for granular paralleling algorithms.Разработан способ получения областей определения функций глобальных зависимостей, основанный на уточненных аппроксимациях множества тайлов. Точное представление границ областей определения функций глобальных зависимостей позволяет избегать избыточных вычислений при выполнении коммуникационных операций и дает больше возможностей для распараллеливания зернистых алгоритмов

Spectral kinetic properties of Yb3+:Na4Y 6F22 and Yb3+:LiLuF4 crystals

Yb3+ (2.7 at.%):Na4Y6F22 and Yb3+(1 at.%):LiLuF4 crystals were grown by the Bridgman-Stockbarger method. We measured the temperature dependences of the thermal conductivity of the crystals and the absorption spectra. We determined the radiative lifetime of the Yb3+ ion in these crystals (1.94 msec and 2.13 msec) and calculated the stimulated emission cross section spectra. © 2007 Springer Science+Business Media, Inc

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin lymphoma. Since its first approval 20 years ago, intravenously administered rituximab has revolutionized the treatment of B-cell malignancies and has become a standard component of care for follicular lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma. For all of these diseases, clinical trials have demonstrated that rituximab not only prolongs the time to disease progression but also extends overall survival. Efficacy benefits have also been shown in patients with marginal zone lymphoma and in more aggressive diseases such as Burkitt lymphoma. Although the proven clinical efficacy and success of rituximab has led to the development of other anti-CD20 monoclonal antibodies in recent years (e.g., obinutuzumab, ofatumumab, veltuzumab, and ocrelizumab), rituximab is likely to maintain a position within the therapeutic armamentarium because it is well established with a long history of successful clinical use. Furthermore, a subcutaneous formulation of the drug has been approved both in the EU and in the USA for the treatment of B-cell malignancies. Using the wealth of data published on rituximab during the last two decades, we review the preclinical development of rituximab and the clinical experience gained in the treatment of hematologic B-cell malignancies, with a focus on the well-established intravenous route of administration. This article is a companion paper to A. Davies, et al., which is also published in this issue